Evaluation of the Abbott ARCHITECT Toxo IgM assay

被引：9

作者：

Sickinger, Eva ^{[2
]}

Braun, Hans-Bertram ^{[2
]}

Praast, Gerald ^{[2
]}

Stieler, Myriam ^{[2
]}

Gundlach, Cordelia ^{[2
]}

Birkenbach, Claudia ^{[2
]}

Prostko, John ^{[1
]}

Palafox, Mary Ann ^{[1
]}

Frias, Edwin ^{[1
]}

Hsu, Stephen ^{[1
]}

Matias, Matthew ^{[1
]}

Pucci, Dominick ^{[1
]}

Hausmann, Michael ^{[2
]}

Sagel, Ulrich ^{[3
]}

Smith, Darwin ^{[1
]}

机构：

[1] Abbott Diagnost, Abbott Pk, IL 60064 USA

[2] Abbott GmbH & Co KG, D-65205 Wiesbaden, Germany

[3] Austrian Agcy Hlth & Food Safety AGES, Inst Med Microbiol & Hyg, A-1096 Vienna, Austria

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2009年 / 64卷 / 03期

关键词：

Toxoplasmosis; Toxo IgM; Acute infection; TOXOPLASMA-GONDII INFECTION; IMMUNOGLOBULIN-M ANTIBODIES; AGGLUTINATION-TEST; PREGNANT-WOMEN; RISK-FACTORS; AVIDITY; DIAGNOSIS; SYSTEM;

D O I：

10.1016/j.diagmicrobio.2009.03.016

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Development of the ARCHITECT Toxo IgM assay has been done to assist the clinician in acute Toxoplasma gondii infection detection, especially in pregnant women. Its use, in conjunction with ARCHITECT Toxo IgG and Toxo Avidity assays, will provide an array of assays particularly useful in the monitoring of pregnant females to determine the risk of maternal transmission of the parasite. Specificity results from 2 testing sites, using populations of pregnant females, hospital patients, and blood donors, demonstrated that the assay has an overall resolved relative specificity of 99.89% (confidence interval, 99.68-99.98%). Relative specificity for pregnant female specimens was 99.95% (n = 2031). Excellent seroconversion sensitivity was observed for the ARCHITECT Toxo IgM assay, which was similar to the Abbott AxSYM Toxo IgM assay (Abbott Laboratories, Abbott Park, IL). In more than 90% of the panels tested, the 1st bleed detected in the serial bleeds was the same for both assays. (C) 2009 Elsevier Inc. All rights reserved.

引用

页码：275 / 282

页数：8

共 50 条

[1] Toxoplasmosis serodiagnosis:: evaluation of Access® Toxo IgM II assay compared to Axsym® Toxo IgM and Vidas® Toxo IgM assays
Decoster, A
Lambert, N
Germaneau, C
Masson, C
ANNALES DE BIOLOGIE CLINIQUE, 2000, 58 (06) : 721 - 727
[2] Evaluation of the Abbott Architect Cyclosporine Assay
Maine, G. T.
Levine, D. M.
Amann, S. M.
Parker, T. S.
Chang, J. S.
Lorey, T.
Hoke, C.
THERAPEUTIC DRUG MONITORING, 2009, 31 (05) : 639 - 639
[3] EVALUATION OF THE ABBOTT ARCHITECT CYCLOSPORINE ASSAY
Levine, D. M.
Amann, S. M.
Parker, T. S.
CLINICAL CHEMISTRY, 2009, 55 (06) : A258 - A259
[4] Analytical evaluation of the Abbott ARCHITECT Sirolimus assay
Maine, G. T.
Kahn, S. E.
Vazquez, D.
Meyer, P.
Dickson, D.
Kenney, D.
Edwards, M.
Haverstick, D. M.
CLINICAL BIOCHEMISTRY, 2008, 41 (14-15) : 1277 - 1277
[5] Evaluation of the Abbott ARCHITECT Chagas prototype assay
Praast, Gerald
Herzogenrath, Joerg
Bernhardt, Stephanie
Christ, Heike
Sickinger, Eva
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2011, 69 (01) : 74 - 81
[6] Evaluation of the restandardised Abbott Architect oestradiol assay
Donaldson, A
Marks, K
Saunders, L
Chapman, RS
CLINICA CHIMICA ACTA, 2005, 355 : S239 - S240
[7] Analytical evaluation of the Abbott ARCHITECT sirolimus assay
Kahn, S. E.
Vazquez, D.
Meyer, P.
Dickson, D.
Kenney, D.
Edwards, M.
Haverstick, M.
CLINICAL CHEMISTRY, 2008, 54 (06) : A14 - A14
[8] Evaluation of Fujirebio Sirolimus assay on the Abbott architect
Gonsorcik, V.
Pederson, E. C.
Castellani, W. J.
CLINICAL CHEMISTRY, 2007, 53 (06) : A85 - A85
[9] EVALUATION OF COPPER ASSAY IN SERUM ON THE ABBOTT ARCHITECT ANALYZER
Coric, J.
Panjeta, M.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S753 - S753
[10] Evaluation of an assay in development for tacrolimus on the Abbott ARCHITECT® analyzer
Baugher, B. W.
Drengler, S.
Rahn, T.
Ramp, J.
Liao, M.
Wong, P. Y.
CLINICAL CHEMISTRY, 2006, 52 (06) : A59 - A59

← 1 2 3 4 5 →